These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1566498)

  • 41. Brequinar sodium suppresses liver allograft rejection and induces permanent tolerance in the rat.
    Knoop M; Cramer DV; Chapman FC; Makowka L
    Transplant Proc; 1993 Feb; 25(1 Pt 1):706-7. PubMed ID: 8438447
    [No Abstract]   [Full Text] [Related]  

  • 42. Induction of antigen-specific tolerance: antigen form and injection route.
    Yoshimura N; Hamashima T; Oka T
    Transplant Proc; 1996 Jun; 28(3):1150-1. PubMed ID: 8658604
    [No Abstract]   [Full Text] [Related]  

  • 43. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent.
    Küchle CC; Thoenes GH; Langer KH; Schorlemmer HU; Bartlett RR; Schleyerbach R
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1083-6. PubMed ID: 1989154
    [No Abstract]   [Full Text] [Related]  

  • 44. Biological characteristics of a novel immunosuppressant, IR-1116, specific for B lymphocytes.
    Matsumoto S; Marui S; Shiho O; Tsukamoto K; Yoshimura N; Oka T
    Transplant Proc; 1993 Feb; 25(1 Pt 1):734-7. PubMed ID: 8382385
    [No Abstract]   [Full Text] [Related]  

  • 45. Additive effects of leflunomide and tacrolimus in prevention of islet xenograft rejection.
    Zhang L; Qi Z; Wu D; Shan S; Ekberg H
    Scand J Immunol; 2004 Mar; 59(3):255-60. PubMed ID: 15030575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion.
    Propper DJ; Woo J; Macleod AM; Thomson AW
    Transplant Proc; 1991 Dec; 23(6):3310-1. PubMed ID: 1721446
    [No Abstract]   [Full Text] [Related]  

  • 47. Leflunomide.
    Cannon GW; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):295-309, vi. PubMed ID: 15172042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinetics of cellular immune response to pig antigens in man.
    Citterio F; Pozzetto U; Fioravanti G; Serino F; Caizzi MP; Castagneto M
    Transplant Proc; 1994 Jun; 26(3):1393-4. PubMed ID: 8029954
    [No Abstract]   [Full Text] [Related]  

  • 49. In vivo use of rapamycin suppresses neither IL-2 production nor IL-2 receptor expression in rat transplant model.
    Hamashima T; Yoshimura N; Ohsaka Y; Oka T; Stepkowski SM; Kahan BD
    Transplant Proc; 1993 Feb; 25(1 Pt 1):723-4. PubMed ID: 8438457
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunological mechanisms governing tolerance to self-major histocompatibility complex antigens after bone marrow transplantation.
    Hess AD; Fischer AC; Horwitz LR; Bright EC; Hess JM
    Transplant Proc; 1995 Feb; 27(1):1370-3. PubMed ID: 7878915
    [No Abstract]   [Full Text] [Related]  

  • 51. Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
    Stojic Vukanic Z; Dimitrijevic M; Colic M; Popovic P; Jandric D
    Transplant Proc; 2001 May; 33(3):2137-8. PubMed ID: 11377478
    [No Abstract]   [Full Text] [Related]  

  • 52. The inhibitory effect of methyl palmitate on heteroagglutinin formation in rats.
    Sebestík V; Majský A; Potmĕsilová I; jelínek J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(4):558-60. PubMed ID: 72712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nature of the unresponsiveness induced by cyclosporin A in rats bearing renal allografts.
    Homan WP; Fabre JW; Morris PJ
    Transplantation; 1979 Nov; 28(5):439-41. PubMed ID: 392840
    [No Abstract]   [Full Text] [Related]  

  • 54. The use of leflunomide in transplantation immunology.
    Waer M
    Transpl Immunol; 1996 Sep; 4(3):181-5. PubMed ID: 8893446
    [No Abstract]   [Full Text] [Related]  

  • 55. Synergy, additivism and antagonism in immunosuppression. A critical review.
    Berenbaum MC
    Clin Exp Immunol; 1977 Apr; 28(1):1-18. PubMed ID: 324671
    [No Abstract]   [Full Text] [Related]  

  • 56. Suppression of graft-versus-host disease and antibody formation by phytohemagglutinin.
    Hunter RL; Millman RB; Lerner EM
    Transplantation; 1969 Oct; 8(4):413-21. PubMed ID: 5384040
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunosuppressive effects of lymphocyte-specific histamine congener treatment of an adoptive transfer model.
    Garlie NK; Khosropour P; Melmon KL
    Ann N Y Acad Sci; 1993 Jun; 685():774-6. PubMed ID: 8363284
    [No Abstract]   [Full Text] [Related]  

  • 58. [Immunomodulating effects of glucagon].
    Kevorkov NN; Kniazev IuA; Gusev EIu
    Probl Endokrinol (Mosk); 1987; 33(5):68-71. PubMed ID: 3321035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of anti-rat lymphocyte antibody on humoral antibody formation.
    James K; Jubb VS
    Nature; 1967 Jul; 215(5099):367-71. PubMed ID: 4168355
    [No Abstract]   [Full Text] [Related]  

  • 60. Isoxazolylthioamides as potential immunosuppressants a combinatorial chemistry approach.
    Albert R; Knecht H; Andersen E; Hungerford V; Schreier MH; Papageorgiou C
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2203-8. PubMed ID: 9873513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.